The reasons for triple therapy in stable COPD patients in Japanese clinical practice

Masaki Miyazaki, Hidetoshi Nakamura, Saeko Takahashi, Shotaro Chubachi, Mamoru Sasaki, Mizuha Haraguchi, Hideki Terai, Makoto Ishii, Koichi Fukunaga, Sadatomo Tasaka, Kenzo Soejima, Koichiro Asano, Tomoko Betsuyaku

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Triple combination therapy involving long-acting muscarinic antagonists long-acting β<inf>2</inf> agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases. Methods: Keio University and affiliated hospitals conducted an observational COPD cohort study, recruiting patients diagnosed as having COPD by pulmonary physicians and those referred for investigation of possible COPD. Their prescription history and clinical course were retrospectively analyzed based on the physicians’ medical records and patient questionnaires. This study was registered with UMIN (UMIN000003470, April 10, 2010). Results: A total of 95 of the 445 COPD patients (21%) were treated with inhaled corticosteroids/long-acting β<inf>2</inf> agonists/long-acting muscarinic antagonists as maintenance therapy, including 12 in COPD Grade I, 31 in Grade II, 38 in Grade III, and 14 in Grade IV, based on the Global Initiative for Chronic Obstructive Lung Disease spirometric grading. For more than half of the patients on triple therapy, the treatment had been intensified due to unsatisfactory improvement of symptoms, and 32% were treated with triple therapy due to comorbid asthma. In contrast, there were COPD patients whose therapy was maintained after starting with triple therapy because of their serious conditions or concurrent exacerbation at diagnosis (8%). Conclusion: Triple therapy was often prescribed in the real-life management of COPD, even in patients whose airflow limitation was not severe. To better control symptoms was the major reason for choosing triple therapy, regardless of the severity of COPD, in Japan.

Original languageEnglish
Pages (from-to)1053-1059
Number of pages7
JournalInternational Journal of COPD
Volume10
DOIs
Publication statusPublished - 2015 Jun 4

Fingerprint

Chronic Obstructive Pulmonary Disease
Therapeutics
Muscarinic Antagonists
Adrenal Cortex Hormones
Physicians
Medical Records
Prescriptions
Japan
Cohort Studies
Asthma
History
Clinical Trials
Lung

Keywords

  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroids
  • Long-acting muscarinic antagonists
  • Long-acting β<inf>2</inf> agonists
  • Triple therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health
  • Health Policy

Cite this

Miyazaki, M., Nakamura, H., Takahashi, S., Chubachi, S., Sasaki, M., Haraguchi, M., ... Betsuyaku, T. (2015). The reasons for triple therapy in stable COPD patients in Japanese clinical practice. International Journal of COPD, 10, 1053-1059. https://doi.org/10.2147/COPD.S79864

The reasons for triple therapy in stable COPD patients in Japanese clinical practice. / Miyazaki, Masaki; Nakamura, Hidetoshi; Takahashi, Saeko; Chubachi, Shotaro; Sasaki, Mamoru; Haraguchi, Mizuha; Terai, Hideki; Ishii, Makoto; Fukunaga, Koichi; Tasaka, Sadatomo; Soejima, Kenzo; Asano, Koichiro; Betsuyaku, Tomoko.

In: International Journal of COPD, Vol. 10, 04.06.2015, p. 1053-1059.

Research output: Contribution to journalArticle

Miyazaki, M, Nakamura, H, Takahashi, S, Chubachi, S, Sasaki, M, Haraguchi, M, Terai, H, Ishii, M, Fukunaga, K, Tasaka, S, Soejima, K, Asano, K & Betsuyaku, T 2015, 'The reasons for triple therapy in stable COPD patients in Japanese clinical practice', International Journal of COPD, vol. 10, pp. 1053-1059. https://doi.org/10.2147/COPD.S79864
Miyazaki, Masaki ; Nakamura, Hidetoshi ; Takahashi, Saeko ; Chubachi, Shotaro ; Sasaki, Mamoru ; Haraguchi, Mizuha ; Terai, Hideki ; Ishii, Makoto ; Fukunaga, Koichi ; Tasaka, Sadatomo ; Soejima, Kenzo ; Asano, Koichiro ; Betsuyaku, Tomoko. / The reasons for triple therapy in stable COPD patients in Japanese clinical practice. In: International Journal of COPD. 2015 ; Vol. 10. pp. 1053-1059.
@article{7da339eb2bbd48f69ed20706238132b9,
title = "The reasons for triple therapy in stable COPD patients in Japanese clinical practice",
abstract = "Background: Triple combination therapy involving long-acting muscarinic antagonists long-acting β2 agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases. Methods: Keio University and affiliated hospitals conducted an observational COPD cohort study, recruiting patients diagnosed as having COPD by pulmonary physicians and those referred for investigation of possible COPD. Their prescription history and clinical course were retrospectively analyzed based on the physicians’ medical records and patient questionnaires. This study was registered with UMIN (UMIN000003470, April 10, 2010). Results: A total of 95 of the 445 COPD patients (21{\%}) were treated with inhaled corticosteroids/long-acting β2 agonists/long-acting muscarinic antagonists as maintenance therapy, including 12 in COPD Grade I, 31 in Grade II, 38 in Grade III, and 14 in Grade IV, based on the Global Initiative for Chronic Obstructive Lung Disease spirometric grading. For more than half of the patients on triple therapy, the treatment had been intensified due to unsatisfactory improvement of symptoms, and 32{\%} were treated with triple therapy due to comorbid asthma. In contrast, there were COPD patients whose therapy was maintained after starting with triple therapy because of their serious conditions or concurrent exacerbation at diagnosis (8{\%}). Conclusion: Triple therapy was often prescribed in the real-life management of COPD, even in patients whose airflow limitation was not severe. To better control symptoms was the major reason for choosing triple therapy, regardless of the severity of COPD, in Japan.",
keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroids, Long-acting muscarinic antagonists, Long-acting β<inf>2</inf> agonists, Triple therapy",
author = "Masaki Miyazaki and Hidetoshi Nakamura and Saeko Takahashi and Shotaro Chubachi and Mamoru Sasaki and Mizuha Haraguchi and Hideki Terai and Makoto Ishii and Koichi Fukunaga and Sadatomo Tasaka and Kenzo Soejima and Koichiro Asano and Tomoko Betsuyaku",
year = "2015",
month = "6",
day = "4",
doi = "10.2147/COPD.S79864",
language = "English",
volume = "10",
pages = "1053--1059",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The reasons for triple therapy in stable COPD patients in Japanese clinical practice

AU - Miyazaki, Masaki

AU - Nakamura, Hidetoshi

AU - Takahashi, Saeko

AU - Chubachi, Shotaro

AU - Sasaki, Mamoru

AU - Haraguchi, Mizuha

AU - Terai, Hideki

AU - Ishii, Makoto

AU - Fukunaga, Koichi

AU - Tasaka, Sadatomo

AU - Soejima, Kenzo

AU - Asano, Koichiro

AU - Betsuyaku, Tomoko

PY - 2015/6/4

Y1 - 2015/6/4

N2 - Background: Triple combination therapy involving long-acting muscarinic antagonists long-acting β2 agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases. Methods: Keio University and affiliated hospitals conducted an observational COPD cohort study, recruiting patients diagnosed as having COPD by pulmonary physicians and those referred for investigation of possible COPD. Their prescription history and clinical course were retrospectively analyzed based on the physicians’ medical records and patient questionnaires. This study was registered with UMIN (UMIN000003470, April 10, 2010). Results: A total of 95 of the 445 COPD patients (21%) were treated with inhaled corticosteroids/long-acting β2 agonists/long-acting muscarinic antagonists as maintenance therapy, including 12 in COPD Grade I, 31 in Grade II, 38 in Grade III, and 14 in Grade IV, based on the Global Initiative for Chronic Obstructive Lung Disease spirometric grading. For more than half of the patients on triple therapy, the treatment had been intensified due to unsatisfactory improvement of symptoms, and 32% were treated with triple therapy due to comorbid asthma. In contrast, there were COPD patients whose therapy was maintained after starting with triple therapy because of their serious conditions or concurrent exacerbation at diagnosis (8%). Conclusion: Triple therapy was often prescribed in the real-life management of COPD, even in patients whose airflow limitation was not severe. To better control symptoms was the major reason for choosing triple therapy, regardless of the severity of COPD, in Japan.

AB - Background: Triple combination therapy involving long-acting muscarinic antagonists long-acting β2 agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases. Methods: Keio University and affiliated hospitals conducted an observational COPD cohort study, recruiting patients diagnosed as having COPD by pulmonary physicians and those referred for investigation of possible COPD. Their prescription history and clinical course were retrospectively analyzed based on the physicians’ medical records and patient questionnaires. This study was registered with UMIN (UMIN000003470, April 10, 2010). Results: A total of 95 of the 445 COPD patients (21%) were treated with inhaled corticosteroids/long-acting β2 agonists/long-acting muscarinic antagonists as maintenance therapy, including 12 in COPD Grade I, 31 in Grade II, 38 in Grade III, and 14 in Grade IV, based on the Global Initiative for Chronic Obstructive Lung Disease spirometric grading. For more than half of the patients on triple therapy, the treatment had been intensified due to unsatisfactory improvement of symptoms, and 32% were treated with triple therapy due to comorbid asthma. In contrast, there were COPD patients whose therapy was maintained after starting with triple therapy because of their serious conditions or concurrent exacerbation at diagnosis (8%). Conclusion: Triple therapy was often prescribed in the real-life management of COPD, even in patients whose airflow limitation was not severe. To better control symptoms was the major reason for choosing triple therapy, regardless of the severity of COPD, in Japan.

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroids

KW - Long-acting muscarinic antagonists

KW - Long-acting β<inf>2</inf> agonists

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=84933574007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933574007&partnerID=8YFLogxK

U2 - 10.2147/COPD.S79864

DO - 10.2147/COPD.S79864

M3 - Article

VL - 10

SP - 1053

EP - 1059

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -